Spherical Pellet Coating for pH-Independent Metoprolol Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current controlled-release dosage forms for metoprolol succinate, such as pharmaceutical pellets, face challenges in achieving consistent release profiles independent of pH and enzymatic activity, with issues like non-uniform pellet shapes and surfaces complicating coating processes and leading to variable drug release.
Innovation Solution
Development of spherical pharmaceutical pellets with a smooth surface, coated with a pH-independent release-controlling coating composed of polyvinyl acetate, triethyl citrate, and talc, ensuring consistent release profiles and stability across different gastrointestinal pH levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tablets are used for controlled release, then the dosage form can be manufactured, but the tablets remain in the stomach for a long time and release is not consistent
Solution Approach 1:
The invention divides the tablet into multiple smaller pellets (microspheres), each containing the active substance. This segmentation allows the dosage form to pass through the stomach more quickly while maintaining controlled release properties in the intestine, resolving the contradiction between stomach residence time and release consistency.
2Ease of manufacture
If extruded pellets are used, then the pellets can be produced, but the pellets have non-uniform shape and rough surface making coating difficult
Solution Approach 1:
The invention applies a coating to the extruded pellets before they are compressed into tablets. This preliminary coating action protects the non-uniform surface from affecting the final product quality, allowing the use of easily manufactured extruded pellets while achieving the desired surface uniformity in the final dosage form.
3Reliability
If pH-controlled release systems are used, then release can be controlled, but the release is altered by food intake and pH variability between individuals
Solution Approach 1:
The invention uses an enteric coating as an intermediary layer that protects the pH-sensitive active substance from the variable pH environment in the stomach and upper intestine. This coating mediates between the active substance and the variable gastrointestinal pH, ensuring consistent release in the lower intestine regardless of food intake or individual pH differences.
4Reliability
If coatings are applied to tablets for controlled release, then release can be influenced, but defective coatings cause uncontrolled release of the total dose
Solution Approach 1:
The invention segments the total dose into multiple small pellets, each with its own coating. If one coating is defective, only a small fraction of the total dose is affected, not the entire dose as would be the case with a coated tablet. This segmentation dramatically reduces the harmful impact of coating defects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides a controlled release of metoprolol succinate with a defined lag-phase and sustained release rate, maintaining therapeutic levels for extended periods, enhancing bioavailability and patient compliance with once-daily dosing.
Implementation Method 1
the release of the active substance takes place independently of the pH value and independently of the action of enzymes
Implementation Method 2
controlled release of the active substance
Data Source
AI summary
A pharmaceutical pellet is provided, comprising a spherical core containing the active substance with a smooth surface and a coating on the core, which controls pH-independent release of the active substance. With a pellet of this kind, the release of the active substance may follow a profile with a lag-phase from 60 minutes to 840 minutes, where during the lag-phase a proportion of 5 wt. % or less of the active substance is released. Furthermore, the active substance may be released from the pellet with a profile such that, after the lag-phase, the release of the active substance is between 3 and 25 wt. % per hour. The active substance is a metoprolol salt.